Phenotype of patients responsive to occipital nerve stimulation for refractory head pain by Paemeleire, Koen et al.
Phenotype of patients responsive to occipital nerve 
stimulation for refractory head pain 
 
 
Koen Paemeleire1*, MD, PhD, Jean-Pierre Van Buyten2*, MD, Machteld Van Buynder2, Dario 
Alicino2, MD, Georges Van Maele3, PhD, Iris Smet2, MD, Peter J. Goadsby4, MD, PhD, 
FRCP 
 
1Department of Neurology, Ghent University Hospital, Ghent, Belgium;  
2Pain Clinic, AZ Nikolaas, Sint-Niklaas, Belgium;  
3Department of Medical Informatics & Statistics, Ghent University Hospital, Ghent, Belgium; 
4Headache Group, Department of Neurology, University of California, San Francisco, San 
Francisco CA, USA 
 
*Both authors contributed equally to this publication 
 
 
 
 
 
 
 
 
Corresponding author: 
Prof. Dr. Peter J. Goadsby 
Headache Group 
Department of Neurology 
University of California, San Francisco 
San Francisco CA, USA 
 
Tel: +1 415 353 8393 
Fax: +1 415 353 9539 
Email: peter.goadsby@ucsf.edu 
 
 
Disclosure: The study has been initiated and designed by the authors. Medtronic Europe 
provided financial support to conduct the study, but was otherwise not involved in the study 
design or publication strategy. PJG has consulted for Medtronic and Boston Scientific on 
matters related to neurostimulation therapy for headache. 
 
  
2
Abstract 
 
Occipital nerve stimulation (ONS) has been employed off-label for medically refractory head 
pain. Identification of specific headache diagnoses responding to this modality of treatment is 
required. Forty-four patients with medically refractory head pain and treated with ONS were 
invited to participate in a retrospective study including a clinical interview and, if necessary, 
an indomethacin test to establish the headache phenotype according to the International 
Classification of Headache Disorders Second Edition (ICHD-II). We gathered data from 
questionnaires before implantation, at one month after implantation, and at long term follow-
up. Twenty-six patients consented and were phenotyped. At one month follow-up and at long 
term follow-up a significant decrease in all pain parameters was noted, as well as in analgesic 
use. Quality of sleep and quality of life improved. Patient satisfaction was generally high as 
80% of patients had ≥ 50% pain relief at long term follow-up. The overall complication rate 
was low, but revisions were frequent. After phenotyping two main groups emerged: eight 
patients had “Migraine without aura” (ICHD-II 1.1) and eight patients with “Constant pain 
caused by compression, irritation or distortion of cranial nerves or upper cervical roots by 
structural lesions” (ICHD-II 13.12). Overuse of symptomatic acute headache treatments was 
associated with less favourable long term outcome in migraine patients. We conclude that 
careful clinical phenotyping may help in defining subgroups of patients with medically 
refractory headache that are more likely to respond to ONS. The data suggest medication 
overuse should be managed appropriately when considering ONS in migraine. A controlled 
prospective study for ONS in ICHD-II 13.12 is warranted.  
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Introduction 
 
Headache is among the most common reasons for patients to seek medical care. Migraine, the 
most common form of disabling primary headache, has been estimated to be the most costly 
neurological disorder in the European Community (1). While considerable developments have 
been made in understanding and treating primary headache, there remains a group of patients 
with difficult to treat headache problems, labeled generically as medically intractable 
headache (2). In general terms these patients have frequent, daily or near-daily headache 
unresponsive to medical therapy. Neuromodulation methods may offer an opportunity to 
address the needs of these highly disabled patients. In a landmark paper, Weiner and Reed 
described excellent outcomes with occipital neurostimulation (ONS) in twelve patients, 
described as having occipital neuralgia (3). On clinical review of this patient cohort and using 
the International Classification of Headache Disorders, Second Edition (ICHD-II) (4), it 
became clear that most of them had chronic migraine and one had hemicrania continua. A 
subsequent PET study  in those with chronic migraine (5) demonstrated persistent activation 
of the dorsolateral pons, as is seen in other imaging studies of migraine (6), and activation of 
thalamus structures when the device was activated. 
 
Given that there has been off-label use of ONS on compassionate grounds in highly disabled 
patients, there is an opportunity to classify those patients using the ICHD-II in order to 
identify potential patient groups for systematic study. Recent experience with chronic cluster 
headache suggests that ONS may be help that disorder (7, 8). Indeed other modalities of 
stimulation have begun to be used in chronic cluster headache, specifically deep brain 
stimulation and these are also proving highly promising (9). Data form the first randomized, 
controlled, prospective trial for ONS for the Treatment of Intractable Migraine headache 
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(ONSTIM trial) have recently become available in abstract form (10). The results indicate that 
ONS may be a promising treatment for some intractable chronic migraine patients, and further 
controlled trials are required.  Interestingly, given the hemicrania continua patient in Weiner 
and Reed’s initial cohort (3), there are nine cases of hemicrania continua treated with ONS 
now reported in the literature and seven benefited from the therapy (11-13). These cases are 
important since hemicrania continua is an indomethacin-sensitive headache, which broadens 
still the range of headache types that may benefit from this approach. 
 
In this retrospective study a cohort of patients, implanted with occipital neurostimulators at a 
single site were invited to attend a clinical evaluation and, if necessary, to undergo an 
indomethacin test in order to clarify the diagnosis. We confirm other reports that chronic 
migraine patients can be treated with this approach adding a note of caution around 
medication overuse, and identify a previously unreported group, Upper Cervical Neuropathic 
Pain (ICHD-II, 13.12), who have a promising outcome. This work was presented in 
preliminary form at the 10th Congress of the European Federation of Neurological Societies 
(14). 
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Methods 
 
Forty-four patients were consecutively treated with ONS for medically refractory headache 
between April 2000 and December 2006 at the AZ Nikolaas Pain Clinic (JPVB, Figure 1). All 
patients underwent a preoperative psychological evaluation. Informed consent was sought 
from all patients by letter to review their clinical data, including a pre-implantation 
questionnaire, a questionnaire at one month following trial stimulation (i.e. before the 
definitive implantation procedure), as well as technical details: implantation date and 
procedure; complications such as dislocations, lead fractures, electrical leakage at the 
connections and infection; and battery replacement. The patients were invited by letter to be 
interviewed by an independent and blinded headache neurologist at the Department of 
Neurology of the Ghent University Hospital (KP). If necessary to make a specific headache 
diagnosis, patients were invited to give their informed consent to undergo an indomethacin 
test, either intramuscular or oral. The indomethacin tests were performed by the treating 
physician at AZ Nikolaas Pain Clinic (JPVB). Patients that entered the study were finally 
invited to fill out the post-implantation questionnaire for a second time at their last visit at AZ 
Nikolaas Pain Clinic, to obtain long term follow-up data. The Ethics Committees of the Ghent 
University Hospital in Ghent and the AZ Nikolaas in Sint-Niklaas approved the study 
(EC/2006/383). 
 
Implantation technique 
Initially, the implantation technique described by Weiner and Reed (3) was used. A 
subcutaneous lead was inserted towards the midline via a lateral incision close to the mastoid 
process. The procedure was done under propofol sedation with a wake up during the 
procedure in order to check the area of paresthesia. With growing experience the technique 
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was adapted and the ONS procedure is now performed under general anesthesia with the 
patient in the prone position and the head in a horseshoe headrest. The incision is made close 
to the occiput, where there is more fat tissue that affords a subcutaneous pocket substantial 
enough for adequate fixation of the lead and leaving a loop. A curved needle (custom made 
by Medtronic Inc., Bakken Research Center, Maastricht, The Netherlands) is pushed from the 
occiput towards the mastoid process in the subcutaneous tissue, to cross the greater, lesser and 
least occipital nerve. The position of the lead is checked with fluoroscopy after the needle has 
been pulled out. An intermediate incision is made in the suprascapular area, again creating a 
pocket, and a second loop is left behind. A third incision is made parallel to the spine at the 
high thoracic level to bury the connection between the lead and the temporary extension lead. 
The connection is fixated to the underlying tissue. The temporary extension lead is tunneled 
laterally over the thoracic wall. After a successful trial period of at least one month, a pocket 
is created in the gluteal area for the implantable pulse generator, a new extension lead is 
tunneled towards the connector and the new connector is secured to the underlying tissue. 
Stimulation parameters, including frequency, pulse width and voltage, were adjusted such that 
all patients experience mild paresthesia in the stimulated area.  
 
Pain questionnaires 
The pre- and post-implantation questionnaires were developed by the Belgian Pain Society, 
and include data on regional distribution of the pain using a pre-printed drawing of the head 
and body, pain severity scores on a visual analogue scale or VAS from 0-10 indicating ‘pain 
at present’, ‘worst pain last week’, ‘lowest pain last week’, ‘average pain last week’, 
percentage pain-free time (0-100%), average daily number of analgesics used, quality of sleep 
on a scale from 1-5, influence of pain on activities of daily living, social activities, 
independence of others, hobbies and need for bed rest (all the five using VAS scores on a 
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scale from 0-10). The post-implantation questionnaire was filled out by every patient after one 
month of stimulation and by twenty-one patients at long term follow-up. This questionnaire 
included data on the subjective area of stimulation on a pre-printed drawing, perceived pain 
relief (‘worse’, ‘too little’, ‘moderate’, ‘largely’, ‘almost complete’, ‘complete’), patient 
satisfaction (‘excellent’, ‘very good’, ‘good’, ‘moderate’, ‘poor’, ‘no effect’ or ‘worse’), and 
the question whether the patient would undergo the procedure again for the same indication, 
but was otherwise identical to the pre-implantation questionnaire. 
 
Clinical interview 
During the clinical interview demographic data, analgesic use, all necessary information to 
make a headache diagnosis according to ICHD-II (4), as well as percentage of pain relief at 
long term follow-up were recorded. To make a diagnosis of medication-overuse headache the 
Appendix Criteria were used (15). Patients were instructed not to discuss their pre-
implantation diagnosis. All clinical data were made available to a second blinded headache 
neurologist (PJG) before clinical diagnoses were assigned. 
 
Indomethacin testing 
To exclude a diagnosis of paroxysmal hemicrania or hemicrania continua an intramuscular 
indomethacin test was performed in some patients with strictly unilateral (attacks of) head 
pain (16). Intramuscular indomethacin tests were performed at the Pain Clinic of AZ Nikolaas. 
Patients had their stimulator turned off in the morning and recorded pain on a VAS from 0-10 
for three hours in a diary. If the head pain reached an intensity of ≥ 5/10 on the VAS, 100 mg 
indomethacin was injected intramuscularly. Pain scores were recorded each hour afterwards 
for the rest of the day. Afterwards the patients received instructions to switch the stimulator 
back on. If the head pain reached an intensity of < 5/10 during the three hours observation 
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period, instructions were given to perform an ambulatory oral indomethacin test. Patients 
would record headache intensity on an hourly basis in a headache diary while under 
indomethacin. Indomethacin was started at 25 mg three times per day for three days. If the 
patient was not pain-free, the indomethacin dose was increased to 50 mg three times per day 
for three days. If the patient was not pain-free, the indomethacin dose was further increased to 
75 mg three times per day for three days. If the patient was not completely pain-free at that 
point in time, the oral indomethacin test was deemed negative. Exclusion criteria for an 
indomethacin test were asthma, renal disease, allergy to acetylsalicylic acid or NSAIDs, 
active peptic ulcer disease and pregnancy. 
 
Data analysis 
The statistical analysis of the data was performed by an independent statistician (GVM) with 
R, a language and environment for statistical computing (17). Univariate comparison of 
unpaired groups was done with the Fisher’s Exact test for categorical data and the non-
parametric Mann-Whitney U-test for the comparison of continuous variables. The non-
parametric Friedman two-way ANOVA test with Wilcoxon matched-pairs signed-ranks test 
as multiple range test was used to compare measurements over the three time intervals. The 
significant level was set at α = 0.05, two-tailed. 
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Results 
 
All forty-four patients consented to have their data used from the questionnaires pre-
implantation and at one month post-implantation. Twenty-six patients consented to undergo 
clinical interview, which took place at the Neurology Department of the Ghent University 
Hospital between December 2006 and April 2007. Data from the questionnaire at long term 
follow-up were additionally obtained from twenty-one of these twenty-six patients. 
 
Overall safety in all 44 patients 
The mean age of all forty-four patients at implantation was 48 years (range 29-75). All forty-
four patients had an occipital component to their head pain and eighteen also had a trigeminal 
component. Twenty-one patients underwent unilateral neurostimulation, ten on the left, 
eleven on the right, and twenty-three patients had bilateral neurostimulation, using one 
electrode in nineteen and two electrodes in four. The mean duration of follow-up was 36 
months (range 7-87 months). The total device time was 1592 months. Fourteen of the forty-
four patients had a total of eighteen revisions. Eleven patients had to have a new lead put in 
place, in two patients because of dislocation, using the initial technique with a lateral incision 
(cf. Methods section), and in the other nine patients because of lead fracture, with four of 
these patients undergoing a second revision again lead replacement. In three cases there was a 
problem with the connection, with pain due to local current leakage, requiring opening of the 
connection and cleaning it. There were two instances of infection, one at the level of the lead 
insert during the trial period, and one later after implantation at the level of the connector due 
to a small skin defect. Both infections were solved with short term antibiotic treatment. 
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Pooled results for the 26 phenotyped patients 
Twenty-six of the forty-four patients (59 %) agreed to be phenotyped. Pooled outcome data 
for this group are summarized in Table 1. Statistically significant improvements were 
obtained on all outcome parameters, both at one month follow-up and at long term follow-up 
when compared to pre-implantation data. The mean percentage long term pain relief was 
63 % (range 0-100 %), and 81 % (21 of 26 patients) of the patients had at least 50 % long 
term pain relief. The outcome on three parameters was significantly worse at long term 
follow-up compared to data at one month post-implantation, including increased ‘lowest pain 
last week’, increased ‘average pain last week’ and decreased percentage time spent pain-free. 
Data from questionnaires on all available parameters were compared between patients that 
volunteered for a clinical interview (n = 26) and those that did not (n = 18) at baseline and at 
one month follow-up. There were no significant differences except for the included patients 
being older (average of 51 versus 44 years old), having less influence of pain on activities of 
daily living and hobbies at baseline, and having less influence of pain on hobbies at one 
month follow-up. 
 
Clinical phenotyping 
The mean age of the twenty-six patients that were phenotyped was 51 years at the time of 
implantation (range 29-75). There were fourteen women and twelve men in this group. An 
indomethacin test was proposed to six patients of whom two refused. All four indomethacin 
tests, of which two were oral and two intramuscular, were negative. The clinical diagnoses for 
all 26 patients fell into nine ICHD-II categories (figure 1). Two main subgroups were 
identified: eight patients with migraine without aura (ICHD-II 1.1) and eight patients with 
“Constant pain caused by compression, irritation or distortion of cranial nerves or upper 
cervical roots by structural lesions” (ICHD-II 13.12). All patients with migraine without aura 
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had an additional diagnosis of medication-overuse headache prior to implantation. All 
migraine patients failed at least four classes of preventive medicines, of which at least three 
were a β-blocker, anticonvulsant, calcium channel blocker or tricyclic antidepressant thus 
fulfilling current criteria for medical intractability (2). We compared all available data 
between both groups ICHD-II 1.1 and ICHD-II 13.12 and found that there were few 
significant differences, except that patients with ICHD-II 13.12 had significantly more pain 
relief (mean 80% versus 47%; n = 8 in both groups) at long term follow-up, and that migraine 
patients were more independent of others at one month follow-up (n = 8 in both groups). The 
latter difference was not seen at long term follow-up. 
 
Patients with migraine 
The eight migraine patients had a mean follow-up of 24 months following implantation (range 
12-60 months). Patient satisfaction at 1 month follow-up was rated excellent by one, very 
good by two and good by five. At long term follow-up one patient indicated no effect, one 
only moderate effect, one a good effect, three very good and one excellent (missing data in 
one patient). At one month follow-up every patient would undergo redo the procedure, but at 
long term follow-up two out of seven patients would not (missing data in one patient). 
Grouped data from the questionnaires at one month and long term follow-up were compared 
with the data pre-implantation. There was a significant reduction on most pain parameters 
(‘actual pain’, p = 0.00557; ‘least pain last week’, p = 0.0118; ‘mean pain last week’, p = 
0.00952; ‘% pain-free’, p = 0.00298) except for the ‘worst pain in the last week’ (p = 0.0539). 
The absolute average value for ’mean pain last week’ decreased from 7/10 VAS score pre-
implantation to 2.4/10 and 4/10 at one month and long term follow-up respectively. Five out 
of seven patients (missing data in one) had at least a three point drop in ‘mean pain last week’ 
at long term follow-up. The use of analgesics was significantly diminished (p = 0.0469). 
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Influence of pain on most activity parameters was not significantly changed, except for an 
increase in social activities (p = 0.0262). Quality of sleep was not significantly changed. 
There were no significant differences between the data at one month follow-up versus at long 
term follow-up, except for a decrease in percentage of time spent pain-free at long term 
follow-up, that went down from 71 to 51% (p = 0.04983). 
 
We considered migraine without aura patients with respect to presence (n = 5) or absence (n = 
3) of medication overuse headache (see Table 2) at long term follow-up. The average 
percentage pain relief at long term follow-up was 47 % for the entire group of eight patients 
(range 0-95%). Despite the small numbers patients with medication overuse had a 
significantly less percentage pain relief at long term follow-up when compared to those 
without (mean of 28% versus 78%; p = 0.0498).  
 
Head pain of cervical origin 
The eight patients suffering from “Constant pain caused by compression, irritation or 
distortion of cranial nerves or upper cervical roots by structural lesions” had a mean follow-up 
of 53 months following implantation (range 32-74 months).All but one patient suffered for at 
least five years from “Constant pain caused by compression, irritation or distortion of cranial 
nerves or upper cervical roots by structural lesions” despite conventional treatments, which 
illustrates the intractable nature of their condition (2). Patients (missing data for one patient) 
rated the procedure as excellent (n = 2), very good (n = 2), or at least good (n = 3) at one 
month post-implantation. At long term follow-up (missing data for one patient) satisfaction 
with the technique was at least good (n = 4), but also very good (n = 1) and excellent (n = 2). 
All patients indicated they would redo the procedure at one month and at long term follow-up 
(with data missing for one patient). From our retrospective interview we ascertained that two 
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of eight patients had maximal pain relief within 24 hours after implantation, five of eight 
patients had an average of 70% (range 40-100%) pain relief within the first 24 hours, all eight 
patients had an average pain relief of 70% (range 20-100%) within seven days. Most patients 
within this group (n = 5) find that switching the stimulator off leads to exacerbation of the 
pain very quickly, within ten minutes to one hour. Delay of pain relief upon switching the 
stimulator back on varies between ten minutes and days. However, two patients are able to 
switch the stimulator off part of the day to save on battery, but switch it on when the pain 
exacerbates. Grouped data from the questionnaires at one month and long term follow-up 
were compared with the data pre-implantation. There was a significant reduction on all pain 
parameters: ‘actual pain’ (p = 0.0211), ‘worst pain in the last week’ (p = 0.00841), ‘least pain 
last week’ (p = 0.0160) and ‘mean pain last week’ (p = 0.0135); the ‘% pain-free’ increased 
from an average pre-implantation value of 13% to 68% and 53% at 1 month and long term 
follow-up respectively (p = 0.0193). The absolute average value for ’mean pain last week’ 
decreased from 7.4/10 VAS score pre-implantation to 2.9/10 and 4.4/10 at one month and 
long term follow-up respectively. Six out of seven patients (missing data in one) had at least a 
three point drop in ‘mean pain last week’ at long term follow-up. The use of analgesics was 
significantly diminished (p = 0.0244) and quality of sleep improved (p = 0.0468). Influence of 
pain on most activity parameters was significantly diminished, specifically activities of daily 
living (p = 0.0331), social activities (p = 0.0295), dependency on others (p = 0.0246) and need 
for bed rest (p = 0.0220), except for hobbies (p = 0.0941). There were no significant 
differences between the data at one month follow-up versus at long term follow-up. The 
overall average percentage pain relief at long term follow-up was 80%. There was no 
significant difference in percentage pain at long term follow-up (see Table 3) between those 
patients with medication overuse (n = 5) and those without medication overuse (n = 3) at long 
term follow-up.  
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Other headache diagnoses 
Diagnoses according to ICHD-II in the remaining ten patients were diverse (see Table 4) and 
included new daily persistent headache (ICHD-II 4.8; n = 2), chronic post-traumatic headache 
attributed to mild head injury (ICHD-II 5.2.2; n = 1) and chronic headache attributed to 
whiplash injury (ICHD-II 5.4; n = 2). One patient suffered from chronic cluster headache, 
probable migraine and medication-overuse headache (ICHD-II 3.1.2, 1.6.1 and A8.2; n = 1) 
Two patients had a combination of migraine with aura (ICHD-II 1.2.1) and ICHD-II 13.12 
and two patients are not classifiable at present because they refused an indomethacin test. 
These ten patients had an average follow-up of 27 months (range 9-68 months). All patients 
scored the efficacy at least good at one month follow-up (n = 8, missing data in two). At long 
term follow-up (missing data in three) only four of seven patients still scored the efficacy at 
least good.  The patients experienced on average 62 % pain relief at long term follow-up 
(range 0-95 %). At long term follow-up six of seven patients would redo the intervention 
(missing data in three).
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Discussion 
 
The data presented suggest that for some subgroups of patients with relatively medically 
refractory headache occipital neurostimulation (ONS) offers an effective, well tolerated and 
comparably safe approach to management. Certainly in this very disabled group such a 
development would be welcome. The data provide support for the further study of ONS in 
migraine and caution investigators to carefully monitor for the potential effects of medication 
overuse when studying ONS. Perhaps more important a cohort of patients with that may be 
described as Upper Cervical Neuropathic Pain (ICHD-II, 13.12). This finding is important 
first, because the patients did well, and secondly, because such patients may not always come 
to attention of neurology and headache specialists thinking about this new treatment modality. 
An important feature of our cohort has been the very careful phenotyping of the cases, 
including indomethacin testing, to provide as clear diagnoses as possible. ONS is a promising 
therapy for a range of patients with challenges to both identify candidates and conduct 
appropriately blinded randomised controlled trials. 
 
Peripheral nerve stimulation, which is a minimally invasive and reversible procedure, is 
increasingly employed in the treatment of certain forms of chronic neuropathic pain and 
certainly preferred over nerve ablation procedures (18). The mechanism of action is 
incompletely understood, but includes an inhibitory input within pain pathways, gate control 
of pain as well as modulation of neurotransmitters in the central nervous system (18, 19). The 
technique of implantation of a occipital neurostimulator was pioneered by Weiner and Reed 
(3) to treat patients with pain that had an occipital focus. Off-label use of ONS has been 
employed on a compassionate basis for highly disabled patients with intractable headache, 
suffering from occipital neuralgia (20), chronic migraine (5), or transformed migraine (21), 
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chronic cluster headache (7, 8), hemicrania continua (12), post-traumatic headache and 
headache of C2 origin (22). ONS is considered a minimally invasive procedure and safety data 
are good (11). The rationale behind the technique in primary headache syndromes, such as 
migraine and cluster headache, is to modulate sensory traffic from the trigeminocervical 
complex (23, 24), either at the level of the second order neurons (25, 26), or possibly in the 
thalamus (5). Given the loss of spatial specificity at the level of the trigeminocervical 
complex, electrical stimulation of the occipital nerve may have an anti-nociceptive effect in 
the territory of the trigeminal as well as the occipital nerves. Interestingly, stimulation of the 
greater occipital nerve in the rat reduces calcitonin gene-related peptide in the jugular blood, 
which is a biomarker of inhibition of the trigeminal system (27). In case of neuropathic pain 
in the occipital territory (ICHD-II 13.12), electrical stimulation of the sensory afferents may 
lead to suppression of Aδ- and C-fibres at the level of the spinal dorsal horn (28, 29). 
 
We embarked on this retrospective study to try to identify subgroups of patients with 
medically refractory headache with an increased likelihood of responding to ONS. Response 
to an occipital nerve block certainly is not useful in predicting therapeutic effect of ONS (8, 
10, 30). In this uncontrolled series all 44 patients had at least an occipital component to their 
head pain, and received uni- or bilateral ONS, mirroring the clinical distribution of the pain.  
 
At one month follow-up post-implantation, patient satisfaction was generally high and all 
patients would theoretically undergo the intervention again for the same indication. Given the 
mean duration of follow-up of three years and a total device time of almost 1600 months, the 
overall complication rate of two infections. However, at least one revision was needed in 
about 30% of patients because of technical problems, which included lead fracture, 
dislocation and connector current leakage. Some of these problems are due to the fact that the 
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material used has not been designed for this purpose but for Spinal Cord Stimulation. It is 
reassuring that not a single neurological deficit was created by the intervention. We only had 
two patients with a dislocated lead and not a single dislocation occurred after the technique 
was adapted by doing a medial incision, leaving loops at two stages and fixing the connector. 
These results are very favourable when compared to earlier results with lead dislocation in all 
patients after 3 years (11).  
 
Twenty-six patients were phenotyped according to the ICHD-II criteria. At long term follow-
up twenty-one individuals indicated they experienced at least 50 % pain relief. These twenty-
six patients had a mean VAS reduction for ‘average pain last week’ of 4.7 at one month post-
implantation and of 3.4 at long term follow-up. The overall satisfaction with the technique 
was high, except for three patients that had no pain relief at long term follow-up. All three 
individuals, two migraine patients and one patient with new daily persistent headache, had 
ongoing medication overuse. When we compared available data from the eighteen that were 
not phenotyped and the twenty-six that were, only few statistically significant differences 
were found, and these did not seem clinically important. For the rest of the discussion we 
speculate that our findings in the phenotyped patients are representative for the entire group. 
 
After subanalysis two main groups of patients were identified, i.e. migraine without aura and 
occipital neuropathic pain, coded in the ICHD-II under 13.12 “Constant pain caused by 
compression, irritation or distortion of cranial nerves or upper cervical roots by structural 
lesions”. Even though both groups only consist of eight patients, and thus statistical power is 
low, some significant differences were found. It appears that ICHD-II 13.12 patients had 
higher percentage pain relief at long term follow-up. This result is influenced by two migraine 
patients with ongoing medication-overuse headache that experienced no pain relief at long 
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term follow-up and that indicated they would not redo the intervention at that time. Indeed, 
the presence/persistence of medication overuse at long term follow-up is a negative predictor 
in migraine patients as the average pain relief for patients with medication-overuse was much 
less than for those without at long term follow-up. This finding is certainly consistent with the 
general concept that medication overuse renders migraine patients more resistant to 
prophylactic therapy. It appears thus that close monitoring of acute headache treatment is 
mandatory to assure long term benefit from the technique. Withdrawal of migraine patients 
from medication overuse is necessary prior to implantation, as it may account for a large part 
of the improvement by itself. 
 
These findings need to be corroborated in randomized, blinded and controlled trials, as a 
placebo effect, regression to the mean and spontaneous improvement certainly may play a 
role in the observed effect. Some individuals did not have long term headache improvement 
after occipital neurostimulator implant, despite improvement in the temporary stimulator trial, 
as has previously been observed (11). Non-specific effects may have waned after permanent 
implantation. An important weakness of the study is that it is retrospective with regard to the 
pain aspects, although this is offset by the long term follow-up and the careful approach to 
phenotyping the cases that has been employed. 
 
Conclusion 
 
Results of ONS for refractory headache are promising, although the concept of intractable 
headache itself needs to be further refined. It must be clear what the purpose of the definition 
of refractory is for as the bar to a referral to an expert should be less than for a new therapy 
that is non-invasive versus an invasive treatment. A number of issues need to be resolved to 
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optimise ONS including stimulus parameters, battery life, and the stimulator itself with regard 
to implantation techniques and associated side effects, such as lead migration. An external 
rechargeable battery would certainly be welcome. Moreover, patient selection criteria, as well 
as predictors for outcome need to be further refined, and tested in clinical trials. Our 
retrospective study and a recent pilot study (22) generate the hypothesis that ICHD-II 13.12 
may be an excellent indication for ONS and a well powered controlled trial would certainly 
be welcome. Careful clinical phenotyping will require close collaboration between pain 
specialists and neurologists, to assign diagnosis according to the ICHD-II. In particular 
migraine patients need to be closely monitored for medication overuse, as is appears to be a 
negative predictor for long term outcome in our study. ONS is promising and challenging for 
all concerned, although the prospect of finding therapies for our most disabled patients is a 
crucial and rewarding pursuit. 
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Figure 1. Study outline.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
44 patients with occipital neurostimulator 
for medically refractory headache 
26 patients in study 18 patients not in study 
± INDO test  
ICHD-II diagnosis 
 
1.1  Migraine without aura 
1.2.1  Typical aura with migraine headache 
1.6.1  Probable migraine without aura 
3.1.2  Chronic cluster headache 
4.8  New daily persistent headache 
5.2.2  Chronic post-traumatic headache attributed to mild head injury 
5.4  Chronic headache attributed to whiplash injury 
13.12  Constant pain caused by compression, irritation or distortion of 
 cranial nerves or upper cervical roots by structural lesions 
A8.2  Medication-overuse headache 
Subanalysis  
1.1 ± A8.2 (n=8) 
13.12 ± A8.2 (n=8) 
Informed consent to use data from pre- and 
post-implantation questionnaires (n=44) 
Informed consent for independent clinical 
interview ± INDO test (n=26) 
Informed consent to use data from 
questionnaire at long term follow-up (n=21) 
Table 1: Pooled results for the twenty-six phenotyped patients 
 
Parameter Pre-implantation At 1 month follow-up At long term follow-up 
1. Pain VAS scores Mean (range) VAS score  Mean (range) VAS score  Mean (range) VAS score  
   Pain at present 7.3 (2.5-10) 2.6 (1-6)♦ 2.6 (1-7)♠ 
   Worst pain last week 8.9 (5.5-10) 4.8 (1-10)♦ 5.7 (1-9)♠ 
   Lowest pain last week 5.3 (1-10) 1.8 (1-4)♦ 2.5 (1-6)♠,♣ 
   Average pain last week 7.3 (3.5-10) 2.6 (1-5.5)♦ 3.9 (1-7)♠,♣ 
2. Long term pain relief   Mean percentage (range) 
   63% (0-100%) 
3. Time spent pain-free Mean percentage (range) Mean percentage (range) Mean percentage (range) 
 7.3% (0-40%) 72.2% (0-100%)♦ 56.7% (0-100%)♠,♣ 
4. Analgesic consumption Mean number (range) of 
analgesics/day 
Mean number (range) of 
analgesics/day 
Mean number (range) of 
analgesics/day 
 2.9 (1-4) 1.5 (0-4)♦ 1.6 (0-4)♠ 
5. Quality of life Mean (range) VAS score Mean (range) VAS score Mean (range) VAS score 
   Influence of pain on   
   activities of daily living 
6.3 (2-9) 3.6 (1-8)♦ 3.6 (1-9)♠ 
   Influence of pain on  
   social activities 
7.4 (2-10) 3.2 (1-8)♦ 3.8 (1-9)♠ 
   Influence of pain on  
   Independence of others 
3.7 (1-10) 1.9 (1-5)♦ 2.1 (1-9)♠ 
   Influence of pain on  
   hobbies 
7.4 (1-10) 3.9 (1-9.5)♦ 4 (1-9)♠ 
   Influence of pain on  
   need for bedrest 
5.8 (1-10) 2.7 (1-8.5)♦ 2.7 (1-5)♠ 
6. Quality of sleep Mean percentage scoring 
sleep at least good 
Mean percentage scoring 
sleep at least good 
Mean percentage scoring 
sleep at least good 
 56% 83%♦ 86%♠ 
♦: significant change (p<0.05) in parameter at 1 month follow-up compared to pre-implantation status 
♠: significant change (p<0.05) in parameter at long term follow-up compared to pre-implantation status  
♣: significant change (p<0.05) in parameter at long term follow-up compared to 1 month follow-up status   
 
Table 2. Detail of migraine patient outcomes 
 
Patient 
number 
Baseline 
ICHD-II 
diagnosis♦  
VAS scores for pain 
pre-implantation 
actual/worst/least/mean 
VAS scores for pain  
at 1 month 
actual/worst/least/mean 
VAS scores for pain 
long term 
actual/worst/least/mean 
% pain relief 
long term 
MO long 
term 
Redo  
long term  
# 1 1.1, A8.2 8,5 9,5 7,5 7,5 1 8 1 2 3 8 2 3 0 yes no 
# 5 1.1, A8.2 3,5 7 2,5 3,5 2 3 1 2 MD 7 3 6 0 yes no 
# 12 1.1, A8.2 4 10 2 6,5 2 9 1 3 1 5 1 2 80 no yes 
# 14 1.1, A8.2 9 10 5 8 1 1 1 1 1 8 1 1 95 no yes 
# 16 1.1, A8.2 8 8 2 5 3 5 1 2 2,5 6,5 2 5 60 no yes 
# 17 1.1, A8.2 9 10 6,5 9,5 4 10 1 4 MD MD MD MD 30 yes MD 
# 24 1.1, A8.2 7 7 7 7 4,5 9 4 4 4,5 9 3 6 60 yes yes 
# 26 1.1, A8.2 9 9 6 9 1 2 1 1 1 5 5 5 50 yes yes 
 
ICHD-II     
1.1, 8.2 
Number of 
patients 
% pain relief      
long term 
MO+ 5 28%* 
MO- 3 78%* 
*p=0.0498   
 
♦1.1: Migraine without aura; A8.2: Medication-overuse headache 
MD = missing data 
MO+/- = with or without medication overuse at long-term follow-up 
Table 3. Detail of outcome of patients suffering from ICHD-II 13.12- Upper Cervical Neuropathic Pain 
 
Patient 
number 
Baseline 
ICHD-II 
diagnosis♦  
VAS scores for pain 
pre-implantation 
actual/worst/least/mean 
VAS scores for pain  
at 1 month 
actual/worst/least/mean 
VAS scores for pain 
long term 
actual/worst/least/mean 
% pain relief 
long term 
MO long 
term 
Redo  
long term  
# 2 13.12 2,5 10 1 3,5 6 9 1 4,5 1 6 1 3 95 yes yes 
# 3 13.12 8 9 7 8 1 1 1 1 4 9 3 6 75 yes yes 
# 7 13.12 10 10 10 10 4 7 4 4 7 9 6 7 80 no yes 
# 8 13.12 7 7,5 4 6,5 4 4 4 3 5,5 5,5 5,5 5,5 100 no yes 
# 9 13.12 7,5 9 4 6 1,5 2,5 1 1 1 1 1 1 100 no yes 
# 13 13.12 7 10 6 8 4,5 4,5 2 3 3 6 3 4,5 72,5 yes yes 
# 19 13.12 9,5 9,5 9,5 9,5 3 3 3 3 MD MD MD MD 65 yes MD 
# 23 13.12 5 9 4 8 3 5,5 2,5 4 3,5 5 3,5 4 56 yes yes 
 
ICHD-II     
1.1, 8.2 
Number of 
patients 
% pain relief      
long term 
MO+ 5 73%* 
MO- 3 93%* 
*not sign.   
 
♦13.12: Constant pain caused by compression, irritation or distortion of cranial nerves or upper cervical roots by structural lesions 
MD = missing data 
MO+/- = with or without medication overuse at long-term follow-up 
  
 
Table 4. Outcome data for all other patients 
 
Patient 
number 
Baseline ICHD-II 
diagnosis♦  
VAS scores for pain 
pre-implantation 
actual/worst/least/mean 
VAS scores for pain  
at 1 month 
actual/worst/least/mean 
VAS scores for pain 
long term 
actual/worst/least/mean 
% pain relief 
long term 
MO long 
term 
Redo  
long term  
# 4 4.8 8 8 1 7 1 2,5 1 1 1 7,5 1 5 0 yes no 
# 6 5.2.2 MD MD MD MD MD MD MD MD MD MD MD MD 52,5 no MD 
# 10 3.1.2, 1.6.1, A8.2 7 10 5 8 4 9 4 5,5 4,5 9 2,5 6 55 yes yes 
# 11 1.2.1, A8.2, 13.12 7 9 7 8 2 4 2 3 2 3 2 2,5 75 yes yes 
# 15 5.4 5,5 5,5 5,5 5,5 2 2 1 2 2 2 2 2 87,5 yes yes 
# 18 5.4 8 9 6 8 MD MD MD MD MD MD MD MD 55 no MD 
# 20 NC 8 9 2,5 6 1 5 1 2 1 3 1 3 95 no yes 
# 21 4.8 10 10 10 10 2 2 1 1,5 2,5 2,5 3 3 85 yes yes 
# 22 NC 8,5 9,5 6,5 8 3 6 2 2,5 MD MD MD MD 15 yes MD 
# 25 13.12, 1.2, A8.2 6,5 7 5 6,5 2 2 1 2 2 2 2 2 95 yes yes 
 
♦1.2.1: Typical aura with migraine headache; 1.6.1: Probable migraine without aura; 3.1.2: Chronic cluster headache; 4.8: New daily persistent 
headache; 5.2.2: Chronic post-traumatic headache attributed to mild head injury; 5.4: Chronic headache attributed to whiplash injury; 13.12: Constant 
pain caused by compression, irritation or distortion of cranial nerves or upper cervical roots by structural lesions; A8.2: Medication-overuse headache; 
NC = not classifiable  
MD = missing data 
 
 
 
 
 
